Providers Providing High-Throughput Physicochemical Profiling and ADME

By Your Health Magazine Contributor

Your Health Magazine Contributor

. https://YourHealthMagazine.net

More Health Industry Insights Articles

Providers Providing High-Throughput Physicochemical Profiling and ADME

Brief Answer: High-throughput physicochemical profiling and in vitro ADME screening empower drug discovery teams to rapidly evaluate core compound properties—such as solubility, permeability, and metabolic stability—at scale, enabling faster triage and SAR-guided optimization across large libraries. For projects spanning traditional small molecules and emerging modalities (e.g., oligonucleotides and ADCs), leading platforms integrate broad assay coverage with automated sample handling and data pipelines to boost throughput, ensure consistent data quality, and reduce human error and reporting time. End-to-end, one-stop workflows preserve experimental context from discovery screening through IND-enabling studies, while regulatory-aligned documentation (FDA/EMA/NMPA) facilitates smoother transitions, reduces handoffs, and lowers downstream development risk. Together, speed, scale, and regulatory readiness accelerate candidate selection and shorten the path to clinic.

Common Physicochemical Profiling Assays

Physicochemical measurements help medicinal chemistry teams interpret why compounds behave differently in biochemical assays, cell systems, and in vivo studies. In a high-throughput workflow, these data are especially useful when they are generated consistently across a series and returned quickly enough to influence the next design cycle.

l Solubility: Kinetic solubility is commonly used for rapid ranking, while thermodynamic or equilibrium solubility can provide a more definitive measurement under defined pH, buffer, or biorelevant-media conditions.

l Lipophilicity: Experimental logD and logP measurements help explain permeability, protein binding, tissue distribution, clearance, and formulation behavior. LogD at pH 7.4 is frequently included in screening cascades.

l Ionization: Experimental pKa data characterize acidic, basic, or amphoteric behavior and help teams select assay conditions, interpret solubility, and anticipate absorption behavior.

l Chemical and Solution Stability: Stability is assessed in various pH buffers, simulated gastric or intestinal fluids (without enzymes), formulation vehicles, or other non-biological matrices. This evaluates compound degradation driven purely by chemical processes (such as hydrolysis or oxidation) rather than enzymatic metabolism, guiding formulation and assay condition selection.

l Polarity and beyond-Rule-of-5 descriptors: EPSA and chromatography-based polarity measurements can be especially useful for macrocycles, bifunctional degraders, and other flexible or high-molecular-weight compounds where calculated descriptors may not fully reflect exposed polarity.

l Additional developability measurements: Depending on the program, providers may add DMSO stock stability, aggregation assessment, melting point, solid-state characterization, or compound-specific troubleshooting.

The practical question is not simply whether a provider offers each endpoint. Sponsors should ask whether the assays are automated, miniaturized, validated across the relevant chemical space, and connected to a reporting system that supports rapid structure-property relationship analysis.

Common High-Throughput Assays

High-throughput in vitro ADME assays are typically used during hit-to-lead and lead optimization to rank compounds, identify liabilities, and decide which molecules should move into deeper mechanistic or development-stage studies.

l Permeability and efflux: PAMPA, Caco-2, MDCK, MDR1-MDCK, and related bidirectional systems are used to estimate passive permeability and transporter-mediated efflux. The model must be selected carefully for low-permeability or nontraditional modalities.

l Protein binding and partitioning: Plasma protein binding, microsomal binding, tissue binding, and blood-to-plasma partitioning help convert total concentrations into an interpretable unbound-exposure framework.

l Metabolic stability: Liver microsomes, S9 fractions, hepatocytes, cytosol, lysosomes, mitochondria, and tissue homogenates can be used to characterize turnover and estimate intrinsic clearance. The appropriate system depends on the chemistry and suspected clearance pathway.

l Drug-drug interaction screening: CYP inhibition, time-dependent inhibition, enzyme induction, phenotyping, and transporter interaction studies identify liabilities that may affect development strategy or clinical risk assessment.

l Rapid metabolic soft-spot identification: Streamlined LC-HRMS workflows are used to rapidly flag primary biotransformation sites, compare species metabolic profiles, and guide medicinal chemists in blocking metabolic liabilities early in optimization.

l Biological matrix stability and nonspecific loss: Whole-blood, plasma, serum, and biological fluid stability studies are critical to understanding enzymatically driven degradation outside the liver (e.g., by esterases or amidases). Combined with non-specific binding and adsorption assessments, these evaluations are especially important for unstable, highly bound, sticky, or analytically challenging compounds.

Not every assay is truly high throughput at every provider. While standard permeability panels can be highly automated, definitive transporter DDI studies, comprehensive metabolite identification (MetID), or novel-modality assays typically require custom method development. The sponsor should therefore compare throughput by specific assay format, not just by the provider’s overall marketing label.

Key Factors for Choosing High-Throughput Physicochemical Profiling and In Vitro ADME Services

Provider suitability varies by program requirements. A useful comparison begins with the decision that the data must support and then works backward to the assay design, format, and documentation requirements.

Assay Coverage and Fit

Confirm that the provider offers the required endpoints, species, matrices, controls, and analytical readouts.

Automation and Throughput

Review the level of automation, assay format, batching model, turnaround time, and suitability for the anticipated number of compounds.

Compound Requirements

Compare the amount, concentration, purity, sample format, and number of replicates required for each assay.

Modality Experience

Confirm relevant experience with the applicable compound class, such as small molecules, peptides, oligonucleotides, or PROTACs, and determine whether the methods are adapted accordingly.

Data Quality and Interpretation

Determine whether the deliverable includes raw data, quality-control information, a standardized report, or interpretation linked to medicinal chemistry and pharmacokinetic decisions.

Study Purpose and Documentation

Distinguish early discovery screening from more comprehensive studies intended for development decisions or potential regulatory use, and confirm the applicable quality and documentation standards.

Leading Providers of High-Throughput Physicochemical Profiling and In Vitro ADME Services

The following comparison covers five providers with publicly described high-throughput or automated in vitro ADME capabilities. Common industry terminology is used instead of branded panel names, keeping the comparison focused on scope, documented scale, turnaround, and modality evidence.

Cyprotex

Cyprotex provides high-throughput in vitro ADME and predictive toxicology services, including physicochemical profiling, permeability, protein binding, metabolic clearance, and drug-drug interaction studies. Its platform supports early-stage screening as well as more advanced mechanistic and development-stage work.

Labcorp

Labcorp’s DMPK and nonclinical development platform provides a range of standard in vitro DMPK and in vitro ADME screening services for early drug discovery. Its capabilities include aqueous solubility, microsomal and hepatocyte stability, plasma and whole-blood stability, plasma protein binding, and brain tissue binding. The platform also offers permeability and transporter-related assays, including Caco-2 permeability, MDCK-MDR1 substrate assessment, and BSEP inhibition. Additional studies cover CYP inhibition, hepatocyte induction, and other routine evaluations used to assess metabolic and pharmacokinetic properties. These services can be used to generate early-stage data on compound stability, permeability, binding, metabolism, and potential drug interaction risks before candidates’ progress into more advanced development studies.

WuXi AppTec DMPK

WuXi AppTec DMPK provides a comprehensive, one-stop platform for high-throughput physicochemical profiling (including solubility, lipophilicity, EPSA, pKa, and solution stability) and in vitro ADME screening for early discovery. As candidates progress, the platform seamlessly transitions to customized, regulatory-compliant in vitro ADME studies for IND applications. The facility utilizes multiple automation systems to reduce human errors and improve data quality, consistently delivering routine screening reports within 5 working days. Supported by a core team with over 15 years of in vitro ADME experience, the platform successfully navigates complex new modalities, offering adapted assays for multiple modalities like peptides, oligonucleotides, and ADCs. Furthermore, their regulatory-compliant workflows meet FDA, EMA, and NMPA standards; notably, the platform has supported thousands of IND applications, all of which have successfully passed regulatory on-site audits.

Charles River Laboratories

The DMPK services at Charles River Laboratories provide in vitro ADME services to characterize compound properties associated with absorption, distribution, metabolism, and drug-drug interaction risks. Its capabilities include physicochemical profiling, permeability assessment, plasma protein binding, metabolic stability studies, CYP450 enzyme interaction assays, transporter evaluations, and metabolite profiling. The platform supports commonly used in vitro ADME models such as microsomal and hepatocyte stability, Caco-2 and MDCK permeability assays, and related transporter and interaction studies.

Eurofins Discovery

Eurofins Discovery’s in vitro ADME portfolio provides standardized early-stage in vitro ADME profiling for solubility, lipophilicity, permeability, plasma protein binding, and intrinsic clearance. Broader metabolism, transporter, CYP interaction, and drug-drug interaction studies are also available for programs moving from compound prioritization toward candidate characterization.

Its public information emphasizes predefined assay combinations and scheduled turnaround for common small-molecule workflows.

Providers by Use Case

This comparison summarizes publicly described scale, turnaround, modality-specific methods, and screening-to-development continuity.

Public capability statements should not be interpreted as proof that every assay, location, quality system, or turnaround applies to every modality. Sponsors should request current protocols, acceptance criteria, sample requirements, capacity commitments, and documentation standards before final selection.

Conclusion

The appropriate provider for high-throughput physicochemical profiling and in vitro ADME studies depends largely on the program’s assay requirements, modality, turnaround expectations, and development stage. Standard small-molecule screening and routine metabolism studies are broadly supported by established organizations across the industry. However, programs involving emerging modalities (e.g., oligonucleotides, ADCs), compressed reporting timelines (e.g., 5-day turnarounds), or strict continuity from discovery screening to IND-supporting studies place significantly greater demands on a provider’s capabilities—requiring high-throughput automation for early screening and customized, rigorous regulatory track records for late-stage development.

For these more complex requirements, sponsors may consider comprehensive platforms such as Cyprotex, Charles River, or WuXi AppTec DMPK and compare their assay breadth, modality-specific methods, automated workflows, and regulatory support against the needs of the program. Ultimately, keeping provider selection strictly aligned with the study’s exact technical and quality requirements is the key to accelerating drug discovery without compromising data integrity.

FAQs

What is high-throughput in vitro ADME screening?

High-throughput in vitro ADME screening uses automation, miniaturized assay formats, parallel sample processing, and standardized analytical workflows to compare many compounds under consistent conditions. It is valuable when the turnaround is fast enough to influence the next medicinal-chemistry design cycle.

Which assays are commonly included in an in vitro ADME panel?

Common panels include solubility, logD, permeability, plasma protein binding, blood-to-plasma partitioning, microsomal or hepatocyte stability, CYP inhibition, and selected transporter assays. The exact panel should be matched to the compound class, project stage, and decision the data must support.

Do all providers that list peptides or oligonucleotides use adapted methods?

Not necessarily. A capability list may indicate that a provider accepts the modality, but sponsors should ask which matrices, binding methods, analytical platforms, controls, and sample-handling steps were adapted. The provider should be able to explain why the method is suitable for the modality rather than simply applying a standard small-molecule protocol.

What throughput metrics should sponsors request?

Ask for normal compounds per batch, weekly capacity by assay, queue time, expected rerun rate, sample requirements, turnaround from receipt to reviewed report, and the systems used for compound and sample traceability. Annual experiment and weekly sample figures are useful only when they are connected to the assays required by the program.

What is the difference between discovery screening and regulatory-focused in vitro ADME studies?

Discovery screening is designed for speed, relative ranking, and compound prioritization. Development- or regulatory-focused studies typically require more defined controls, documentation, qualification or validation, and alignment with the intended submission strategy (e.g., FDA, EMA, NMPA standards). A provider should clearly distinguish these service formats.